Quick Takeaways
- Ceva Animal Health and Mitsui & Co. announced the creation of Ceva Bussan Animal Health, a new joint venture combining Bussan Animal Health (BAH) and Ceva Japan. As part of the transaction, Mitsui transferred 60% of its shareholding in BAH to Ceva, making Ceva the controlling shareholder of the new entity
- The joint venture combines BAH’s 75-year presence in Japan’s animal health market with Ceva’s global livestock and companion animal portfolio, multichannel capabilities, and pipeline innovation. BAH generated ~€40M in revenue in 2025 and brings an established veterinary network, while Ceva Japan contributes commercial, marketing, regulatory, and product expertise across swine, ruminant, and pet health segments
- Ceva Bussan Animal Health is expected to strengthen customer engagement, support future product launches, and expand operational scale in Japan’s animal health market. In parallel, Mitsui also made an additional strategic equity investment in Ceva Animal Health, further deepening the long-standing partnership between the two companies
Why It Matters?
Ceva is using this JV to turn Japan from a peripheral presence into a true platform market, bolting its global livestock and pet portfolio onto Bussan Animal Health’s 75‑year brand, field force, and ~€40M business to create a full‑line player with greater launch and service capacity.
For Mitsui, shifting 60% of BAH into Ceva’s control and adding more equity in Ceva deepens a long‑running bet that animal health will be a durable growth engine, while giving Ceva Bussan Animal Health a clearer operating owner, faster decision‑making, and a stronger base to introduce pipeline innovation and multichannel OTC pet offerings across Japan’s highly relationship‑driven veterinary market.
Source: Ceva Animal Health
